Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 2:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 8,144 matching trials from the live ClinicalTrials.gov search.
Filters: Phoenix, Arizona Clear all
Not yet recruiting Not applicable Interventional

Accelerated Flap Coverage Versus Standard Timing in the Treatment of Severe Lower Extremity Musculoskeletal Injuries

NCT07828613
View directory record Official record
Conditions
Open Tibia Fracture, Open Dislocation of Ankle, Extremity Fracture Lower, Extremity Injuries Lower
Interventions
Accelerated Flap Coverage Surgery, Standard of Care Flap Timing
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
31
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 19, 2026, 2:22 AM EDT
Completed Phase 1Phase 2 Interventional

A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury

NCT00036062
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Acute Lung Injury
Interventions
Sivelestat
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2006 · Synced Oct 19, 2026, 2:22 AM EDT
No Longer Available No phase listed Expanded access

Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHD

NCT00759018
View directory record Official record
Conditions
Graft vs Host Disease, Graft-Versus-Host Disease
Interventions
remestemcel-L
Biological
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
2 Months to 17 Years
U.S. locations
24
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 19, 2026, 2:22 AM EDT
Recruiting No phase listed Observational

Diagnostic and Therapeutic Applications of Microarrays in Lung Transplantation

NCT02812290
View directory record Official record
Conditions
Lung Transplant Rejection
Interventions
Lung transplant biopsy bites.
Procedure
Lead sponsor
University of Alberta
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
4
States / cities
Phoenix, Arizona • Baltimore, Maryland • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 19, 2026, 2:22 AM EDT
Completed Phase 2 Interventional

RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)

NCT04832724
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, Wet Age-related Macular Degeneration
Interventions
RGX-314
Genetic
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Phoenix, Arizona • Sun City, Arizona • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 19, 2026, 2:22 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years

NCT03338296
View directory record Official record
Conditions
Obesity
Interventions
lorcaserin hydrochloride XR, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
278 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
16
States / cities
Phoenix, Arizona • Bell Gardens, California • Long Beach, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 19, 2026, 2:22 AM EDT
Recruiting Phase 3 Interventional

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

NCT04293562
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Dexrazoxane Hydrochloride, Etoposide, Fludeoxyglucose F-18, Gemtuzumab Ozogamicin, Gilteritinib Fumarate, Liposome-encapsulated Daunorubicin-Cytarabine, Magnetic Resonance Imaging, Methotrexate, Mitoxantrone Hydrochloride, Positron Emission Tomography, Questionnaire Administration, Therapeutic Hydrocortisone
Procedure · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
6 Months to 21 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
186
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 143 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 19, 2026, 2:22 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia

NCT04409262
View directory record Official record
Conditions
COVID-19 Pneumonia
Interventions
Remdesivir, Tocilizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
38
States / cities
Phoenix, Arizona • Chula Vista, California • Irvine, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Oct 19, 2026, 2:22 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Unidos: Linking Individuals to Social Determinant and Community Health Services

NCT04124224
View directory record Official record
Conditions
Chronic Disease, Community Health Workers
Interventions
Unidos
Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
7
States / cities
Nogales, Arizona • Phoenix, Arizona • Tucson, Arizona + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Oct 19, 2026, 2:22 AM EDT
Completed Phase 3 Interventional Results available

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

NCT01225562
View directory record Official record
Conditions
Myocardial Infarction, Cardiovascular Death, Atherothrombosis, Stroke
Interventions
Ticagrelor 90 mg, Ticagrelor 60 mg, Ticagrelor Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years to 130 Years
Enrollment
21,379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
250
States / cities
Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 247 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2016 · Synced Oct 19, 2026, 2:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Detection of Gut Metabolites in Mother's Milk Following Juice Intake

NCT04596254
View directory record Official record
Conditions
Healthy Diet
Interventions
Pomegranate Juice
Other
Lead sponsor
Amazentis SA
Industry
Eligibility
20 Years to 40 Years · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 19, 2026, 2:22 AM EDT
Active, not recruiting Phase 2 Interventional

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

NCT04233866
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions
Fluorouracil, Gemcitabine, Gemcitabine Hydrochloride, Leucovorin, Leucovorin Calcium, Liposomal Irinotecan, Nab-paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
70 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
760
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 501 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 19, 2026, 2:22 AM EDT
Completed Phase 4 Interventional

A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes

NCT00240253
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
pramlintide acetate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
34
States / cities
Phoenix, Arizona • Concord, California • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 19, 2026, 2:22 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT00786201
View directory record Official record
Conditions
Pulmonary Fibrosis
Interventions
Placebo, CNTO 888 1 mg/kg, CNTO 888 5 mg/kg, CNTO 888 15 mg/kg
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2015 · Synced Oct 19, 2026, 2:22 AM EDT
Terminated Phase 3 Interventional

Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

NCT06790966
View directory record Official record
Conditions
Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck, Unresectable Head and Neck Squamous Cell Carcinoma
Interventions
Combination Treatment of PDS0101 and Pembrolizumab, Pembrolizumab Monotherapy
Combination Product · Drug
Lead sponsor
PDS Biotechnology Corp.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
28
States / cities
Phoenix, Arizona • Greenbrae, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 19, 2026, 2:22 AM EDT
Terminated Phase 3 Interventional Results available

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment

NCT02548351
View directory record Official record
Conditions
Non Alcoholic Steatohepatitis (NASH)
Interventions
Obeticholic Acid, Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
2,477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
175
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 116 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 19, 2026, 2:22 AM EDT
Completed Not applicable Interventional

A Double-Blind Randomized Clinical Trial of a Rifabutin Regimen in the Treatment of Mycobacterium-Avium Complex (MAC) Bacteremia in Patients With AIDS

NCT00001995
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Rifabutin
Drug
Lead sponsor
Pharmacia
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
22
States / cities
Phoenix, Arizona • Harbor City, California • Irvine, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 2:22 AM EDT
Recruiting Phase 2 Interventional

EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

NCT07287670
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
MTX-474, Placebo
Biological · Other
Lead sponsor
Mediar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
23
States / cities
Phoenix, Arizona • La Jolla, California • Loma Linda, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 19, 2026, 2:22 AM EDT
Withdrawn Phase 3 Interventional

Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma

NCT00323570
View directory record Official record
Conditions
Acquired Bleeding Disorder, Trauma
Interventions
activated recombinant human factor VII
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
42
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2012 · Synced Oct 19, 2026, 2:22 AM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis

NCT03682705
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
Elsubrutinib, Upadacitinib, Placebo for elsubrutinib, Placebo for upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
78
States / cities
Huntsville, Alabama • Mesa, Arizona • Peoria, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 19, 2026, 2:22 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Multi-Center Study to Evaluate the Efficacy and Safety of Sildenafil Cream (3.6%) in Premenopausal Patients With Female Sexual Arousal Disorder

NCT04948151
View directory record Official record
Conditions
Female Sexual Arousal Disorder
Interventions
Sildenafil, Placebo
Drug
Lead sponsor
Strategic Science & Technologies, LLC
Industry
Eligibility
21 Years and older · Female only
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
51
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Oct 19, 2026, 2:22 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated

NCT07553429
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Low dose BI 3812465, Medium dose BI 3812465, High dose BI 3812465
Biological
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
28
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Arcadia, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 19, 2026, 2:22 AM EDT
Completed Phase 2 Interventional Results available

Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study

NCT00903331
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
ACT-064992 (macitentan), Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2014 · Synced Oct 19, 2026, 2:22 AM EDT
Recruiting Not applicable Interventional

REmote Virtual Inspiration: Vitality and Energy

NCT07675681
View directory record Official record
Conditions
Implementation Science, Women Health, Disability Physical, Meditation, Tai Chi
Interventions
Accesible Tai Chi/Qigong (TCQ), Health Education Videos (HEV)
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
35 Years to 64 Years · Female only
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 19, 2026, 2:22 AM EDT